Any current/future capex/capital investment/strategic investment?

Total CAPEX planned around Rs. 130-140 crore this year, approximately Rs. 100 crore in the current financial year and Rs. 50 crore in the next year. (Page 12, Page 8) Out of Rs. 320 crore overall CAPEX, Rs. 160 crore is to be spent soon; Rs. 100 crore already spent on Pashamylaram facility, to be capitalized by Q3; facilities in Vizag and formulations expected to be ready by end of next year's Q3. (Page 10) Additional maintenance CAPEX around Rs. 30-40 crore separate from new CAPEX. (Page 11) Rs. 150 crore pending CAPEX is planned, with investment ongoing in occupational exposure level f

Future growth expectations in sales/revenue/volumes?

Commercial CRAMS revenue is expected to be around Rs.180-190 crore for the current year, with a possibility of reaching up to Rs.190 crore, though Q2 numbers may not repeat consistently. Specialty Chemicals revenue is anticipated to grow modestly from Rs.210 crore to approximately Rs.220-230 crore in the full year, with a 5-10% growth range. Regular CRAMS may grow at about 10-20% over the next six months and FY’21, subject to customer success and normal business conditions. Two more specialty chemical molecules are in early development, expected to become commercial around FY’21 or FY’22. Over

Future growth expectations in earnings/operating earnings/profits/EPS?

Earnings growth is reflected in a 62% increase in half-year income, 115% in EBITDA, and 128% in net profit (Page 1). Specialty Chemicals revenue might see a 5-10% growth from Rs. 210 crore to about Rs. 220-230 crore annually (Pages 8 and 14). Commercial CRAMS guidance remains Rs. 180-190 crore for FY’20, with possibilities up to Rs. 190 crore, but quarterly steady-state numbers are uncertain due to order lumpiness (Pages 2, 8, 14). Core CRAMS may grow by 10-20% over the next six months barring customer attrition (Page 2). R&D expenses expected around $10 million annually; some ongoing

Current/ Expected Orderbook/ Pending Orders?

The order book or pending orders are discussed in terms of molecules in different phases (P1, P2, P3, commercial). There is a net addition of only one molecule during the year due to attrition and addition, with about 40% portfolio churn (Page 10). The company cannot give steady-state quarterly orderbook or steady revenue from commercial molecules due to variable sales timelines which can be once a year or once in 15-18 months (Page 14). Commercial CRAMS revenue was Rs. 107 crore this quarter, with total CRAMS at Rs. 206 crore (Page 2). Guidance on commercial CRAMS revenue for full year FY'20

IN US

Sale is live|00:00:00left today

Suven Life Sciences LtdQ3 FY19Healthcare Services

Suven Life Sciences Ltd Q3 FY19 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹268Market Cap: ₹5.6K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Commercial CRAMS revenue is expected to be around Rs.180-190 crore for the current year, with a possibility of reaching up to Rs.190 crore, though Q2 numbers may not repeat consistently.
→Specialty Chemicals revenue is anticipated to grow modestly from Rs.210 crore to approximately Rs.220-230 crore in the full year, with a 5-10% growth range.
→Regular CRAMS may grow at about 10-20% over the next six months and FY’21, subject to customer success and normal business conditions.
→Two more specialty chemical molecules are in early development, expected to become commercial around FY’21 or FY’22.
→Overall CAPEX is Rs.130-140 crore in the current year and Rs.100-120 crore next year, supporting growth.
→Some fluctuation in quarterly revenue is expected due to lumpiness in order timing and product launches.
→Future growth is cautiously optimistic but dependent on client approvals and clinical trial success of key molecules.

Margin guidance

Category 3

→Earnings growth is reflected in a 62% increase in half-year income, 115% in EBITDA, and 128% in net profit (Page 1).
→Specialty Chemicals revenue might see a 5-10% growth from Rs. 210 crore to about Rs. 220-230 crore annually (Pages 8 and 14).
→Commercial CRAMS guidance remains Rs. 180-190 crore for FY’20, with possibilities up to Rs. 190 crore, but quarterly steady-state numbers are uncertain due to order lumpiness (Pages 2, 8, 14).
→Core CRAMS may grow by 10-20% over the next six months barring customer attrition (Page 2).
→R&D expenses expected around $10 million annually; some ongoing molecule developments may impact future growth but with inherent uncertainties (Page 11).
→Specialty chemicals revenue expected stable till FY’22, pending new molecule launches (Page 10).
→Visibility of growth beyond six months limited; projections are based on short-term visibility and can vary (Pages 2, 10, 14).

3 more insights locked — sign up free to unlock

Fundraise plans

- No explicit mention of plans for new fundraising through debt or equity in the provided pages. - Existing debt of Rs.150 crore is discussed, with debt staying with the Suven Pharma entity post-demerger. - CAPEX plans of around Rs.130-140 crore for the current year and about Rs.100 crore the next year are mentioned, but no indication that new fundraising is needed for these. - Rising Pharma's consolidation is pending due to US bankruptcy proceedings; no new investment infusion is currently necessary as per Venkat Jasti. - Cash balance of Rs.150 crore including mutual funds is available; cash generation is expected, to partly fund CAPEX and operations. - No direct mention of planned equity raising or further debt borrowings; emphasis is on utilizing existing funds and proceeds. In summary, based on the transcript, there is no current or imminent new fundraising through debt or equity planned.

Order book

→The order book or pending orders are discussed in terms of molecules in different phases (P1, P2, P3, commercial).
→There is a net addition of only one molecule during the year due to attrition and addition, with about 40% portfolio churn (Page 10).
→The company cannot give steady-state quarterly orderbook or steady revenue from commercial molecules due to variable sales timelines which can be once a year or once in 15-18 months (Page 14).
→Commercial CRAMS revenue was Rs. 107 crore this quarter, with total CRAMS at Rs. 206 crore (Page 2).
→Guidance on commercial CRAMS revenue for full year FY'20 is Rs. 180-190 crore, potentially going up to Rs. 190 crore (Page 2).
→CAPEX related to expanding capacity is ongoing to meet order demand, with facilities expected to come online end of next year (Page 7, Page 6).

Capex plans

Yes

→Total CAPEX planned around Rs. 130-140 crore this year, approximately Rs. 100 crore in the current financial year and Rs. 50 crore in the next year. (Page 12, Page 8)
→Out of Rs. 320 crore overall CAPEX, Rs. 160 crore is to be spent soon; Rs. 100 crore already spent on Pashamylaram facility, to be capitalized by Q3; facilities in Vizag and formulations expected to be ready by end of next year's Q3. (Page 10)
→Additional maintenance CAPEX around Rs. 30-40 crore separate from new CAPEX. (Page 11)
→Rs. 150 crore pending CAPEX is planned, with investment ongoing in occupational exposure level facility in Pashamylaram, to be commercialized soon. (Page 6)
→CAPEX expected to support capacity expansion for CRAMS and generic business growth, but only six months visibility currently available. (Page 6)
→No major CAPEX anticipated for Rising Pharma as it is a development and distribution company without major asset base. (Page 14)

How does Suven Life Sciences Ltd rank vs peers in Healthcare Services?

Pro feature

1Suven Life Sciences Ltd

Rev 3Mar 3

See full Healthcare Services sector rankings

Want more stocks like Suven Life Sciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio